Discordance among aggressiveness characteristics of hepatocellular carcinoma: Portal vein thrombosis and multifocality, related to tumor size, but not to serum alpha-fetoprotein level.

[1]  B. Carr,et al.  EMT and Inflammation: Crossroads in HCC , 2022, Journal of Gastrointestinal Cancer.

[2]  B. Magro,et al.  Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria , 2021, Cancers.

[3]  A. Gasbarrini,et al.  Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter , 2021, The International journal of biological markers.

[4]  A. Gasbarrini,et al.  Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs , 2021, Cancers.

[5]  Yewei Zhang,et al.  Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma , 2020, Journal of hepatocellular carcinoma.

[6]  B. Carr,et al.  Trends in Tumor Indices in Relation to Increased Hepatocellular Carcinoma Size: Evidence for Tumor Evolution as a Function of Growth , 2020, Journal of Gastrointestinal Cancer.

[7]  Mingyue Zhu,et al.  Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma , 2020, Journal of Cancer Research and Clinical Oncology.

[8]  B. Carr,et al.  Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria , 2020, Journal of Gastrointestinal Cancer.

[9]  B. Carr,et al.  Inflammatory Mechanisms of HCC Development , 2020, Cancers.

[10]  B. Carr,et al.  Macroscopic Portal Vein Thrombosis in HCC Patients , 2018, Canadian journal of gastroenterology & hepatology.

[11]  B. Carr,et al.  Validation of a Liver Index and Its Significance for HCC Aggressiveness , 2017, Journal of Gastrointestinal Cancer.

[12]  M. Zoli,et al.  A Liver Index and its Relationship to Indices of HCC Aggressiveness , 2016, Journal of integrative oncology.

[13]  Jianyong Liu,et al.  Diagnostic accuracy of des‐gamma‐carboxy prothrombin versus α‐fetoprotein for hepatocellular carcinoma: A systematic review , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[14]  Jun Yu,et al.  CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma , 2014, Oncotarget.

[15]  Lan Wei,et al.  Epithelial to Mesenchymal Transition is Associated with Shorter Disease-Free Survival in Hepatocellular Carcinoma , 2014, Annals of Surgical Oncology.

[16]  Lequn Li,et al.  Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. , 2014, World journal of gastroenterology.

[17]  A. Venook,et al.  A review of hepatocellular carcinoma (HCC) staging systems. , 2013, Chinese clinical oncology.

[18]  M. Zoli,et al.  Alpha‐fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis , 2012, Hepatology.

[19]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[20]  T. Pawlik,et al.  Biology of Hepatocellular Carcinoma , 2008, Annals of Surgical Oncology.

[21]  B. Carr,et al.  Causes of Death in Patients with Unresectable Hepatocellular Carcinoma , 2007, Digestive Diseases and Sciences.

[22]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[23]  B. Carr,et al.  Identification of 2 large size HCC phenotypes, with and without associated inflammation. , 2022, Clinics and Practice.